Currently, there are 60.85M common shares owned by the public and among those 53.50M shares have been available to trade.
The company’s stock has a 5-day price change of -72.54% and -80.45% over the past three months. PLRX shares are trading -76.69% year to date (YTD), with the 12-month market performance down to -80.78% lower. It has a 12-month low price of $7.18 and touched a high of $18.00 over the same period. PLRX has an average intraday trading volume of 640.79K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -71.37%, -75.50%, and -75.86% respectively.
Institutional ownership of Pliant Therapeutics Inc (NASDAQ: PLRX) shares accounts for 96.28% of the company’s 60.85M shares outstanding.
It has a market capitalization of $186.82M and a beta (3y monthly) value of 1.07. The earnings-per-share (ttm) stands at -$3.34. Price movements for the stock have been influenced by the stock’s volatility, which stands at 22.62% over the week and 9.92% over the month.
Earnings per share for the fiscal year are expected to decrease by -32.10%, and -8.14% over the next financial year. EPS should grow at an annualized rate of -12.58% over the next five years, compared to -22.68% over the past 5-year period.
Looking at the support for the PLRX, a number of firms have released research notes about the stock. Wells Fargo stated their Equal Weight rating for the stock in a research note on Feb-11-25, with the firm’s price target at $41-$4. RBC Capital Mkts coverage for the Pliant Therapeutics Inc (PLRX) stock in a research note released on February 11, 2025 offered a Sector Perform rating with a price target of $4. H.C. Wainwright on their part issued Neutral rating on February 11, 2025.
